1E6.F - Eagle Pharmaceuticals, Inc.
| Previous close | 17.70 |
| Open | 17.50 |
| Bid | 0.00 x 20000 |
| Ask | 0.00 x 20000 |
| Day's range | 17.50 - 17.50 |
| 52-week range | 16.90 - 46.00 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 233.903M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.26 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.50 |
ZacksEagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.88% and 3.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall St.Eagle Pharmaceuticals (NASDAQ:EGRX) shareholders have endured a 55% loss from investing in the stock five years ago
We think intelligent long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an...
- Simply Wall St.
Eagle Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
Eagle Pharmaceuticals ( NASDAQ:EGRX ) Full Year 2022 Results Key Financial Results Revenue: US$316.6m (up 85% from FY...
ZacksEagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksShould Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksAre Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Simply Wall St.
Can Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Performance Keep Up Given Its Mixed Bag Of Fundamentals?
Eagle Pharmaceuticals' (NASDAQ:EGRX) stock is up by 8.7% over the past three months. However, the company's financials...
- Simply Wall St.
Industry Analysts Just Made A Substantial Upgrade To Their Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Revenue Forecasts
Shareholders in Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) may be thrilled to learn that the analysts have just...
ZacksEagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksIs Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksNuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Investors in Eagle Pharmaceuticals (NASDAQ:EGRX) have unfortunately lost 50% over the last three years
Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) shareholders should be happy to see the share price up 20% in the last...
ZacksNew Strong Sell Stocks for September 26th
EGRX, ACCO and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2022.
ZacksNew Strong Sell Stocks for September 9th
EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.
- Simply Wall St.
Time To Worry? Analysts Are Downgrading Their Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Outlook
The latest analyst coverage could presage a bad day for Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ), with the analysts...
Motley FoolEagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript
At this time, I would like to welcome everyone to the Eagle Pharmaceuticals second quarter 2022 financial results. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, investor relations for Eagle Pharmaceuticals. This is Lisa Wilson, investor relations for Eagle Pharmaceuticals.
ZacksEagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
ZacksTEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.
- Simply Wall St.
Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Eagle Pharmaceuticals (NASDAQ:EGRX) has had a rough three months with its share price down 14%. But if you pay close...